GLP-3 Deep Dive

What is "GLP-3" (The Triple Agonist)?

​

In the world of metabolic research, "GLP-3" is the colloquial term for the latest breakthrough in peptide science: the Triple Hormone Receptor Agonist (often associated with the compound Retatrutide).

Think of your metabolism like a car.

​

• GLP-1 (Semaglutide) presses the brake on your appetite.

• GLP-1 + GIP (Tirzepatide) presses the brake on appetite and tunes up the engine for better fuel efficiency.

• GLP-3 (Triple Agonist) does both of those things, but adds a third component—Glucagon—which effectively presses the gas pedal on your body's energy burning systems.

 It targets three specific receptors in the body simultaneously:

1. GLP-1: Regulates appetite and insulin.

2. GIP: Helps break down fats and sugar.

3. Glucagon: Increases energy expenditure (calorie burning) and liver function.

​

How is it different from GLP-1 (Semaglutide)?

 

The primary difference is the mechanism of action.

​

GLP-1 (Single Agonist):

• Focus: Satiety (feeling full) and blood sugar control.

• How it works: It mimics a hormone in the gut that tells the brain you are full and slows down digestion.

• Result: You eat less because you aren't hungry.

 

GLP-3 (Triple Agonist):

• Focus: Satiety, Fat Metabolism, and Energy Expenditure.

• How it works: It keeps the appetite suppression of GLP-1, adds the fat-processing help of GIP, and introduces Glucagon. Glucagon is the game-changer here—it signals the liver to release stored energy and increases the body's metabolic rate.

• Result: You eat less and your body burns more calories at rest (thermogenesis).

​

Can You Use Both GLP-1 and GLP-3 Together?

 

The short answer is: No, it is generally not recommended.

Because "GLP-3" is a triple agonist, it already contains the GLP-1 mechanism. If a subject is researching GLP-3, they are already stimulating the GLP-1 receptor.

Adding a separate GLP-1 (like Semaglutide) on top of GLP-3 would likely result in:

1. Receptor Saturation: The receptors are already being signaled; adding more may not yield better results.

2. Increased Side Effects: Doubling up significantly raises the risk of gastrointestinal distress (nausea, gastroparesis) and hypoglycemia (low blood sugar).

Most researchers transition from a GLP-1 to a GLP-3, rather than stacking them.

​

Scientific Context & Research Data

​

The excitement surrounding Triple Agonists stems from clinical trials (specifically regarding the drug Retatrutide) causing "unprecedented" results in weight management and liver health.

​​

1. Superior Weight Reduction In Phase 2 clinical trials published in the New England Journal of Medicine, the triple agonist demonstrated weight reduction significantly higher than current market standards.

• The Data: At 48 weeks, participants on the highest dose achieved a mean weight reduction of 24.2%. For context, typical GLP-1 trials often show 15% reduction, and GLP-1/GIP trials around 20%.

​​

2. Liver Fat Reduction (NAFLD) The addition of the Glucagon receptor specifically targets the liver. This drives the metabolism of lipids (fats) in the liver, clearing out fatty deposits.

• The Data: In a sub-study of the same trial, research subjects saw an average of 86% reduction in liver fat, with many achieving complete resolution of fatty liver markers.

​

3. Improved Metabolic Markers Triple agonists have shown robust improvements in blood pressure, glycated hemoglobin (HbA1c), and lipid profiles (cholesterol/triglycerides).

​

References for Further Research

 

For those interested in the primary literature regarding Triple Hormone Receptor Agonists:

​

1. Jastreboff AM, et al. "Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." The New England Journal of Medicine. 2023.

   • Highlight: Documents the 24.2% weight reduction mechanism.

2. Sanyal AJ, et al. "Retatrutide for the treatment of metabolic dysfunction-associated steatotic liver disease." The Lancet. 2023.

   • Highlight: Documents the massive reduction in liver fat content.

3. Knerr PJ, et al. "Next generation GLP-1/GIP/glucagon triple agonists." Molecular Metabolism. 2023.

   • Highlight: Explains the biochemistry of how targeting the Glucagon receptor increases resting energy expenditure.

​

​

​

Disclaimer The information on this website is provided for educational and informational purposes only. PureForma Labz offers peptides specifically for laboratory research. These products are not reviewed or approved by the FDA and are not intended for human use or for diagnosing, treating, curing, or preventing any medical condition. The content on this site should not be taken as medical guidance. For any questions about medications, supplements, or wellness decisions, it’s best to speak with a licensed healthcare professional.

​

​

​